MIRAMAR, Fla. — October 16, 2025 — Leads & Copy — HCW Biologics Inc. (NASDAQ: HCWB) will present three posters at the Society for Immunotherapy of Cancer’s 40th Annual Meeting, November 5-9, 2025, in National Harbor, Maryland. The presentations will showcase results from IND enabling studies of the company’s lead drug candidates based on its novel TRBC platform technology.
The company’s T-Cell Receptor β-Chain Constant Region platform enables the creation of multiple classes of immunotherapeutic compounds: Multi-Functional Immune Cell Stimulators, Second-Generation Immune Checkpoint Inhibitors, and Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers.
Poster presentations will take place on November 7 and 8, and will cover a Multi-Specific Targeting Fusion and Enhanced Immune Cell Engager (Class III TRBC Compound), Second-Generation Immune Checkpoint Inhibitors (Class II TRBC Compound) and Multi-Functional Immune Cell Stimulators (Class I TRBC Compound).
Dr. Peter Rhode, Chief Scientific Officer and Vice President of Clinical Operations, can be reached at PeterRhode@HCWBiologics.com.
Source: HCW Biologics Inc.
